About this trial
investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under ultrasound guidance with experienced gynecologist and to look for the results including: laboratory evidence through hormonal study ultrasound proof of ovarian follicle development. premature ovarian insufficiency is characterized by early loss of ovarian function (less than 40 years of age) manifested by menstrual irregularity or amenorrhea with elevated levels of gonadotropin hormones and low estrogen and anti-Mullerian hormone.
Autologous use of stem cells from bone marrow are alternative safe minimal manipulative products that can provide a solution to this clinical problem without the need for oocyte donation program.
Eligibility criteria
Qualifiers
clinical diagnosis of premature Ovarian insufficiency.
ineffective hormonal therapy.
biochemical evidence of high gonadotropins.
Disqualifiers
solid or hematological malignancies.
bleeding disorders.
rejection of the procedure.
Trial design
Treatments tested in this trial
- autologous bone marrow cells injection
Treatment groups
Sponsors and collaborators
abdulmajeed hammadi
Lead sponsor
Global Stem Cell Center, Baghdad
Sponsor institution